TICKERNERD
Menu
MMSIMMSIHealthcare · Medical Instruments & Supplies

MMSI Stock Forecast: Merit Medical Systems, Inc. Price Predictions for 2026-2027

Last close, 9 Sept 2026
$87
−0.22% on the day

The 11 Wall Street analysts covering Merit Medical Systems, Inc. hold a median 12-month price target of $100 — +14.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 8 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$5.2B
Ticker Nerd rank
92 / 100
Median analyst target
$100
Analysts covering
11
Revenue$418.8M+9.5% y/y
Operating income$60.5M
Net income$38.8M
Free cash flow$51.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.8%
1M
−2.1%
YTD
−1.1%
1Y
−4.9%
From 52W high
−6.4%
From 52W low
+44.6%
$60
$93
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MMSI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Merit Medical Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
92 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
97
Volatility
90
Quality
86
Value
76
Growth
71
Issuance
61
Momentum
60
Accruals
53
Size
23

Revisions (97): Analysts have, on balance, been raising their forecasts.

Accruals (53): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (23): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MMSI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MMSI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120Oct 25Jan 26Apr 26Jul 26MMSIHigh $123Median $100Low $83

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
9 Buy2 Hold0 Sell
Low $83Median $100High $123

The green dot is the last close — the median target sits +14.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
13 Aug 2026B of A SecuritiesMaintainsNeutral$92 → $97
11 Aug 2026BTIGReiteratesBuy$105
3 Aug 2026Canaccord GenuityMaintainsBuy—
3 Aug 2026Canaccord GenuityMaintainsBuy$85 → $94
31 July 2026BTIGMaintainsBuy$100 → $105
31 July 2026BTIGMaintainsBuy—
31 July 2026JP MorganMaintainsOverweight—
31 July 2026JP MorganMaintainsOverweight$77 → $95
31 July 2026NeedhamMaintainsBuy$90 → $101
31 July 2026NeedhamMaintainsBuy—
31 July 2026Piper SandlerMaintainsOverweight$96 → $106
31 July 2026Piper SandlerMaintainsOverweight—
31 July 2026Wells FargoMaintainsEqual-Weight$74 → $83
31 July 2026Wells FargoMaintainsEqual-Weight—
1 May 2026Canaccord GenuityMaintainsBuy$90 → $85
1 May 2026Canaccord GenuityMaintainsBuy—
1 May 2026JP MorganMaintainsOverweight—
1 May 2026JP MorganMaintainsOverweight$95 → $77
1 May 2026NeedhamMaintainsBuy$101 → $90
1 May 2026NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MMSI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MMSI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Sept 2026, Merit Medical Systems, Inc. returned −4.9% against +18.5% for the S&P 500, dividends included.

MMSI vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26MMSIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MMSI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+5.7%
Analysts raising
8
Analysts cutting
0
Fundamentals

Merit Medical Systems, Inc. (MMSI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
36.0×

Cheaper than 21% of US stocks

Price / sales
3.3×

Cheaper than 38% of US stocks

Price / book
3.1×

Cheaper than 33% of US stocks

EV / EBITDA
16.5×

Cheaper than 20% of US stocks

Growth & margins
Revenue growth (YoY)
9.5%

Higher than 51% of US stocks

Earnings growth (YoY)
19.1%

Higher than 57% of US stocks

Gross margin
51.4%

Higher than 64% of US stocks

Operating margin
14.5%

Higher than 72% of US stocks

Net margin
9.2%

Higher than 68% of US stocks

Returns & dividend
Return on equity
9.2%

Higher than 62% of US stocks

Return on assets
4.9%

Higher than 76% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Merit Medical Systems, Inc. (MMSI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Merit Medical Systems, Inc. has a market value of $5.2B and an enterprise value of $5.6B.

  • Revenue in the twelve months to 30 June 2026: $1.6B. The latest quarter grew 9.5% year on year.

  • Net income over the same four quarters: $145.6M, a 9.2% net margin.

  • Diluted earnings per share, trailing twelve months: $2.42.

  • Free cash flow in the twelve months to 30 June 2026: $199.8M, after $83.7M of capital spending.

  • Shares outstanding: 59.7M.

  • Trailing P/E: 36.0×; forward P/E: 18.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Merit Medical Systems, Inc. employs 7,500 people — $211K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 10 Sept 2026

Data provided by Twelve Data

Peers

MMSI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
MMSIMerit Medical Systems, Inc.$5.2B
92
STVNStevanato Group SpA$5.5B
64
TFXTeleflex, Inc.$6.1B
81
NVSTEnvista Holdings Corp.$4.5B
99
BLCOBausch + Lomb Corp.$6.3B
87
MMEDMiniMed Group, Inc.$6.5B
2
ICUIICU Medical, Inc.$4.0B
96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Merit Medical Systems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MMSI news & analysis

Merit Medical to Participate in Upcoming Investors Conferences in September

GlobeNewsWire · 4 Sept 2026neutral

Merit Medical Systems announced that its management is scheduled to participate in several upcoming investor conferences in September. The company did not disclose additional details beyond the planned appearances.

Why it matters — An MMSI watcher would care because management's participation at investor conferences provides opportunities for the company to present its business to the investment community.

Here's Why You Should Add Merit Medical Stock to Your Portfolio Now

Zacks Investment Research · 2 Sept 2026positive

Zacks Investment Research highlights Merit Medical's broad portfolio, R&D investments and the WRAPSODY opportunity as growth drivers, while noting tariffs, China pressure and competition as risks. The piece frames these factors as supporting continued momentum for the company.

Why it matters — MMSI watchers would care because the coverage reinforces the company's growth narrative while flagging the key risks that could shape its outlook.

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

Zacks Investment Research · 27 Aug 2026neutral

A Zacks Investment Research article highlights oncology innovation driving new cancer treatment options, naming Iovance, Merit Medical and Kura as companies advancing cancer-focused therapies and technologies.

Why it matters — The article positions Merit Medical among oncology-focused companies advancing cancer therapies and technologies, potentially raising visibility of its oncology segment with investors.

Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?

Zacks Investment Research · 24 Aug 2026neutral

Zacks reviewed Merit Medical's investment case, noting its growth story is strengthening through product launches, acquisitions, and therapeutic offerings that broaden its mix. However, the firm's premium valuation was highlighted as raising the execution bar.

Why it matters — MMSI watchers would care because the piece points to improving growth drivers while flagging that the stock's elevated valuation leaves less room for execution missteps.

Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves?

Zacks Investment Research · 24 Aug 2026neutral

Zacks reports that Merit Medical's stock rose 22.2% over the past month, supported by stronger second-quarter growth and a raised 2026 outlook, while noting valuation and tariff risks remain.

Why it matters — The report highlights both the drivers behind MMSI's recent share-price gain and key risks, offering insight for investors tracking the company's performance.

FAQ

Frequently asked questions about MMSI stock

What is the MMSI stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Merit Medical Systems, Inc. have a median 12-month price target of $100, with estimates ranging from $83 to $123. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MMSI stock a buy right now?

Of the 11 analysts covering Merit Medical Systems, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Merit Medical Systems, Inc. 92 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MMSI?

As at 8 Sept 2026, Merit Medical Systems, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (97 of 100).

Will MMSI stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +14.7% from the last close, and Ticker Nerd's factor model ranks Merit Medical Systems, Inc. 92 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MMSI stock forecast for 2030?

No analyst covering Merit Medical Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MMSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $83 to $123 over the next 12 months.

How has MMSI stock performed over the past year?

Merit Medical Systems, Inc. returned -4.9% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Merit Medical Systems, Inc. do?

Merit Medical Systems, Inc. is a medical device company that develops, manufactures, and markets disposable products used in interventional, diagnostic, and therapeutic procedures.

What is the latest news on MMSI?

The most recent item we track (GlobeNewsWire, 4 Sept 2026): "Merit Medical to Participate in Upcoming Investors Conferences in September". Merit Medical Systems announced that its management is scheduled to participate in several upcoming investor conferences in September. The company did not disclose additional details beyond the planned appearances.

Company

About Merit Medical Systems, Inc.

Merit Medical Systems, Inc. is a medical device company that develops, manufactures, and markets disposable products used in interventional, diagnostic, and therapeutic procedures. Merit Medical Systems, Inc. serves a wide range of clinical specialties through its Cardiovascular and Endoscopy segments, with offerings that support cardiology, radiology, oncology, critical care, gastroenterology, pulmonology, and thoracic surgery. Its product portfolio includes access devices, drainage and embolotherapy tools, guide wires, balloon dilators, inflation devices, procedure kits, hemostasis solutions, and other single-use technologies designed for minimally invasive care. The company also provides products used in interventional oncology, spine procedures, cardiac rhythm management, electrophysiology, and cardiovascular critical care. Headquartered in South Jordan, Utah, Merit Medical Systems, Inc. plays a role in supplying hospitals, clinicians, and procedure centers with specialized tools for modern medical interventions.

CEO Ms. Martha Goldberg Aronson · 7,500 employees · United States · https://www.merit.com